Hospital
Adventist Health Clearlake Hospital INC.
Adventist Health Clearlake Hospital INC. was paid $35.14M by Medicaid between Jan 2018 and Nov 2024, across 347 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoADVENTIST HEALTH CLEARLAKE HOSPITAL INC.
CLEARLAKE, CA 95422
CLEARLAKE, CA 95422
33aNPI1124018031assigned 10/24/2005
33bProvider typeCritical Access Hospital
28Total paid$35.14M
24GClaims934,885
24DCodes billed347
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#2 of 30
Median peer was paid$3.14M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PRIDGEN, PARKER controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 104,955 | $4.43M | |
| 2019 | 115,655 | $4.38M | |
| 2020 | 118,879 | $3.93M | |
| 2021 | 146,605 | $5.41M | |
| 2022 | 158,511 | $6.17M | |
| 2023 | 163,373 | $6.21M | |
| 2024incomplete | 126,907 | $4.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 69,065 | 59,053 | $7.91M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 12% | 37,015 | 32,833 | $4.06M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.1% | 31,774 | 6,151 | $1.45M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 3,943 | 3,847 | $1.35M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.5% | 4,462 | 4,417 | $1.24M |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.5% | 3,713 | 2,774 | $868K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 3,881 | 3,786 | $742K |
| 97750 | 1.9% | 7,419 | 3,781 | $675K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 6,366 | 5,985 | $639K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.7% | 4,420 | 4,385 | $593K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 3,597 | 3,279 | $475K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.3% | 1,025 | 1,021 | $472K |
335 more codes
| 80053 | Comprehensive metabolic panel | 1.3% | 56,780 | $471K |
| 97139 | 1.3% | 12,756 | $447K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.2% | 17,594 | $435K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 5,843 | $431K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 9,092 | $414K |
| 99201 | 1.2% | 1,926 | $406K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.1% | 3,765 | $386K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 28,286 | $358K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,696 | $343K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,541 | $337K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,316 | $322K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,562 | $315K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 866 | $290K |
| 80061 | Lipid panel | <1% | 27,713 | $258K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,647 | $240K |
| J3490 | Unclassified drugs | <1% | 19,523 | $237K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,923 | $233K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 456 | $228K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,019 | $223K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 7,983 | $223K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,217 | $215K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,433 | $204K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,379 | $200K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,344 | $188K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,001 | $186K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 418 | $168K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 24,228 | $167K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,469 | $151K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 8,938 | $138K |
| 73030 | <1% | 3,777 | $133K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,254 | $133K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,398 | $131K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 958 | $129K |
| 76770 | <1% | 999 | $128K | |
| 73630 | <1% | 3,660 | $117K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 775 | $116K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,883 | $114K |
| 82607 | <1% | 11,068 | $114K | |
| 72100 | <1% | 2,718 | $112K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,980 | $110K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,870 | $109K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,833 | $109K |
| 99070 | <1% | 7,364 | $107K | |
| 93017 | <1% | 769 | $106K | |
| 97010 | <1% | 2,187 | $100K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 246 | $96K |
| 73130 | <1% | 2,509 | $96K | |
| 72110 | <1% | 1,485 | $94K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 192 | $93K |
| 84439 | <1% | 13,919 | $89K | |
| 83605 | <1% | 9,580 | $88K | |
| 73610 | <1% | 2,139 | $87K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 14,690 | $85K |
| 73564 | <1% | 2,015 | $83K | |
| 76642 | <1% | 838 | $79K | |
| 81001 | <1% | 26,514 | $79K | |
| 76536 | <1% | 834 | $76K | |
| 72141 | <1% | 178 | $75K | |
| 83880 | <1% | 2,997 | $75K | |
| 76801 | <1% | 730 | $69K | |
| 73110 | <1% | 1,544 | $66K | |
| 90715 | <1% | 1,306 | $66K | |
| 80306 | <1% | 3,440 | $63K | |
| 72040 | <1% | 1,482 | $60K | |
| 86481 | <1% | 1,075 | $59K | |
| 74018 | <1% | 2,007 | $58K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,702 | $58K |
| 73562 | <1% | 1,700 | $57K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,344 | $56K |
| 80074 | <1% | 1,612 | $55K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,674 | $52K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,108 | $52K |
| 87186 | <1% | 6,351 | $51K | |
| 94729 | <1% | 1,225 | $51K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 120 | $49K |
| 73221 | <1% | 105 | $48K | |
| 94060 | <1% | 834 | $47K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,836 | $47K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,240 | $46K |
| 73502 | <1% | 932 | $46K | |
| 84484 | <1% | 5,077 | $46K | |
| 83735 | <1% | 9,106 | $45K | |
| 82746 | <1% | 4,004 | $44K | |
| 93971 | <1% | 212 | $44K | |
| 86803 | <1% | 4,304 | $44K | |
| 83690 | <1% | 8,128 | $43K | |
| 93880 | <1% | 150 | $43K | |
| 74022 | <1% | 623 | $42K | |
| 87806 | <1% | 1,609 | $41K | |
| 87040 | <1% | 3,421 | $38K | |
| 0450 | Emergency room services | <1% | 283 | $38K |
| 72070 | <1% | 810 | $38K | |
| 84153 | <1% | 2,838 | $37K | |
| 94726 | <1% | 732 | $37K | |
| 84481 | <1% | 2,697 | $36K | |
| 83970 | <1% | 1,320 | $36K | |
| 82728 | <1% | 3,541 | $35K | |
| 87077 | <1% | 5,335 | $34K | |
| 59025 | Fetal non-stress test | <1% | 881 | $33K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 507 | $33K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 935 | $33K |
| 96367 | <1% | 370 | $32K | |
| 84425 | <1% | 1,692 | $31K | |
| 87507 | <1% | 83 | $31K | |
| 84145 | <1% | 1,631 | $30K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 65 | $29K |
| 87522 | Neg quan hep c or qual rna | <1% | 786 | $28K |
| 84403 | <1% | 1,400 | $28K | |
| 70486 | <1% | 107 | $28K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,577 | $26K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,595 | $25K |
| 81025 | <1% | 7,061 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 952 | $23K |
| Z7502 | <1% | 597 | $22K | |
| 72050 | <1% | 353 | $22K | |
| 73080 | <1% | 487 | $22K | |
| 87070 | <1% | 3,302 | $22K | |
| 86780 | <1% | 2,389 | $22K | |
| 87340 | <1% | 2,928 | $22K | |
| 83540 | <1% | 4,630 | $22K | |
| 86038 | <1% | 1,979 | $21K | |
| 71250 | <1% | 60 | $21K | |
| 86141 | <1% | 2,235 | $20K | |
| 87480 | <1% | 1,340 | $20K | |
| 87510 | <1% | 1,340 | $19K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,268 | $18K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 584 | $18K |
| 85610 | <1% | 5,932 | $18K | |
| 87400 | <1% | 1,425 | $18K | |
| 86762 | <1% | 1,432 | $18K | |
| 82043 | <1% | 4,305 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,124 | $16K |
| 93350 | <1% | 123 | $15K | |
| 87081 | <1% | 2,732 | $14K | |
| 86003 | <1% | 172 | $14K | |
| 85027 | <1% | 2,791 | $13K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,166 | $13K |
| 71271 | <1% | 67 | $13K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,193 | $13K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 84 | $13K |
| 83550 | <1% | 2,381 | $13K | |
| 80143 | <1% | 750 | $13K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,903 | $13K |
| 86140 | <1% | 3,073 | $12K | |
| 93925 | <1% | 53 | $12K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,271 | $12K |
| 80179 | <1% | 723 | $12K | |
| 86703 | <1% | 1,199 | $12K | |
| 80076 | <1% | 2,129 | $11K | |
| 76870 | <1% | 108 | $11K | |
| 87088 | <1% | 1,277 | $11K | |
| 97165 | <1% | 104 | $11K | |
| 85379 | <1% | 1,385 | $10K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,429 | $10K |
| 86317 | <1% | 882 | $9K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 72 | $9K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $8K |
| 82670 | <1% | 396 | $8K | |
| 85652 | <1% | 4,458 | $8K | |
| 85730 | <1% | 1,765 | $8K | |
| 84466 | <1% | 859 | $8K | |
| 86900 | <1% | 2,657 | $8K | |
| 73140 | <1% | 278 | $8K | |
| 82248 | <1% | 2,293 | $8K | |
| 86376 | <1% | 792 | $8K | |
| 73590 | <1% | 197 | $8K | |
| 84550 | <1% | 2,523 | $8K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 16 | $7K |
| 95806 | <1% | 12 | $7K | |
| 82805 | <1% | 289 | $7K | |
| 12001 | <1% | 219 | $7K | |
| 83001 | <1% | 529 | $7K | |
| 86592 | <1% | 1,902 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 820 | $6K |
| 77066 | Tomosynthesis, mammo | <1% | 26 | $6K |
| 86480 | <1% | 107 | $6K | |
| 84100 | <1% | 1,876 | $6K | |
| 87581 | <1% | 244 | $6K | |
| 87486 | <1% | 244 | $6K | |
| 94644 | <1% | 165 | $6K | |
| 86901 | <1% | 2,657 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 822 | $5K |
| 10060 | <1% | 143 | $5K | |
| 74019 | <1% | 129 | $5K | |
| 86430 | <1% | 1,153 | $5K | |
| 85014 | <1% | 1,853 | $5K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $5K |
| 73560 | <1% | 146 | $5K | |
| 82962 | <1% | 1,251 | $5K | |
| 86850 | <1% | 2,076 | $4K | |
| 82550 | <1% | 889 | $4K | |
| 83021 | <1% | 281 | $4K | |
| 87205 | <1% | 1,318 | $4K | |
| 82948 | <1% | 1,732 | $4K | |
| 73521 | <1% | 90 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 86 | $4K |
| 85018 | <1% | 1,921 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 608 | $4K |
| 86705 | <1% | 438 | $4K | |
| 76857 | <1% | 70 | $4K | |
| 73090 | <1% | 98 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 395 | $4K |
| 82570 | <1% | 980 | $4K | |
| 87210 | <1% | 1,128 | $3K | |
| 86704 | <1% | 375 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 323 | $3K |
| 84480 | <1% | 310 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 521 | $3K |
| 83516 | <1% | 246 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 140 | $3K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 282 | $3K |
| 86735 | <1% | 330 | $3K | |
| 86413 | <1% | 41 | $3K | |
| 86765 | <1% | 327 | $3K | |
| 86800 | <1% | 280 | $3K | |
| 78451 | <1% | 40 | $3K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 33 | $3K |
| 83615 | <1% | 629 | $3K | |
| 81329 | <1% | 27 | $3K | |
| 83002 | <1% | 225 | $3K | |
| 82950 | <1% | 791 | $3K | |
| 84460 | <1% | 734 | $3K | |
| 84702 | <1% | 244 | $3K | |
| 85651 | <1% | 1,215 | $2K | |
| 82785 | <1% | 165 | $2K | |
| 84270 | <1% | 146 | $2K | |
| 84156 | <1% | 944 | $2K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 13 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 327 | $2K |
| 83655 | <1% | 221 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 297 | $2K |
| 82947 | <1% | 882 | $2K | |
| 82784 | <1% | 230 | $2K | |
| 0012A | <1% | 51 | $2K | |
| 86364 | <1% | 168 | $2K | |
| 73100 | <1% | 52 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 50 | $2K |
| 97799 | <1% | 55 | $2K | |
| 83525 | <1% | 247 | $2K | |
| 81003 | <1% | 768 | $2K | |
| 71101 | <1% | 26 | $2K | |
| 87807 | <1% | 174 | $2K | |
| 82140 | <1% | 149 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 46 | $2K |
| 87147 | <1% | 381 | $1K | |
| 77080 | <1% | 25 | $1K | |
| 73620 | <1% | 43 | $1K | |
| 83050 | <1% | 254 | $1K | |
| 86200 | <1% | 186 | $1K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 127 | $1K |
| 86235 | <1% | 34 | $1K | |
| 86787 | <1% | 122 | $1K | |
| 93246 | <1% | 39 | $1K | |
| 82105 | <1% | 95 | $1K | |
| 93000 | <1% | 28 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 90 | $993.40 |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $968.24 |
| 85045 | <1% | 314 | $888.46 | |
| 0011A | <1% | 29 | $874.35 | |
| 87045 | <1% | 85 | $856.32 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 45 | $812.62 |
| 84436 | <1% | 158 | $804.66 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 14 | $800.80 |
| 86225 | <1% | 72 | $799.65 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 28 | $733.75 |
| 83520 | <1% | 58 | $709.71 | |
| 82150 | <1% | 148 | $689.76 | |
| 84207 | <1% | 27 | $682.46 | |
| 99499 | <1% | 56 | $679.45 | |
| 72081 | <1% | 15 | $674.38 | |
| 82274 | <1% | 54 | $617.22 | |
| 80164 | <1% | 65 | $590.49 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 27 | $584.00 |
| 82565 | <1% | 159 | $579.41 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 42 | $541.92 |
| 84154 | <1% | 41 | $538.74 | |
| 86160 | <1% | 46 | $514.99 | |
| 73600 | <1% | 12 | $478.68 | |
| 93248 | <1% | 15 | $468.06 | |
| 76882 | <1% | 24 | $444.69 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 63 | $433.63 |
| 82247 | <1% | 119 | $415.64 | |
| 82977 | <1% | 72 | $394.76 | |
| 84450 | <1% | 113 | $391.35 | |
| 86431 | <1% | 89 | $385.93 | |
| 87209 | <1% | 26 | $351.56 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 29 | $336.56 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 25 | $290.40 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 15 | $263.24 |
| 82533 | <1% | 24 | $261.29 | |
| 80178 | <1% | 54 | $256.51 | |
| 87899 | <1% | 30 | $252.59 | |
| 84681 | <1% | 13 | $213.96 | |
| 80069 | <1% | 44 | $212.16 | |
| 85007 | <1% | 84 | $192.36 | |
| J1815 | Injection, insulin, per 5 units | <1% | 32 | $191.44 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 235 | $186.17 |
| 82172 | <1% | 14 | $184.10 | |
| 86308 | <1% | 51 | $180.26 | |
| 84479 | <1% | 41 | $179.16 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 16 | $176.52 |
| 87177 | <1% | 26 | $174.02 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,030 | $166.12 |
| 84146 | <1% | 12 | $164.28 | |
| 83721 | <1% | 26 | $155.50 | |
| 86694 | <1% | 14 | $145.74 | |
| 86708 | <1% | 14 | $132.60 | |
| 84165 | <1% | 13 | $124.15 | |
| Z7610 | <1% | 12 | $118.75 | |
| 86039 | <1% | 12 | $109.12 | |
| 83020 | <1% | 12 | $104.88 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 12 | $95.15 |
| 36415 | Collection of venous blood by venipuncture | <1% | 154 | $92.17 |
| 87276 | <1% | 15 | $89.55 | |
| 87275 | <1% | 15 | $88.95 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 15 | $85.14 |
| 87324 | <1% | 12 | $82.24 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 15 | $80.12 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 32 | $71.36 |
| 82310 | <1% | 16 | $63.14 | |
| 82272 | <1% | 39 | $54.14 | |
| 87046 | <1% | 15 | $51.89 | |
| 84132 | <1% | 12 | $49.05 | |
| 84155 | <1% | 12 | $38.48 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 132 | $10.28 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 310 | $7.26 |
| 3078F | 0% | 71 | $0.00 | |
| 1159F | 0% | 4,099 | $0.00 | |
| 1160F | 0% | 3,352 | $0.00 | |
| 99001 | 0% | 31 | $0.00 | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | 0% | 30 | $0.00 |
| 3008F | 0% | 3,923 | $0.00 | |
| 3074F | 0% | 117 | $0.00 | |
| 3079F | 0% | 35 | $0.00 | |
| 90686 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPRIDGEN, PARKER (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Adventist Health Clearlake Hospital INC. | Clearlake, CA | $78.57M |
| Adventist Health Clearlake Hospital INC. | Paradise, CA | $74.62M |
| Willits Hospital INC. | Willits, CA | $15.00M |
| Ukiah Adventist Hospital | Ukiah, CA | $14.62M |
| Adventist Health Mendocino Coast | Fort Bragg, CA | $7.74M |
| Willits Hospital INC | Willits, CA | $6.04M |
| Adventist Health Clearlake Hospital INC. | Corning, CA | $5.66M |
| Adventist Health Clearlake Hospital, INC | Lower Lake, CA | $4.14M |
| Adventist Health Clearlake Hospital INC | Lakeport, CA | $3.34M |
| Adventist Health Clearlake Hospital, INC | Lucerne, CA | $2.88M |
| Adventist Health Clearlake Hospital INC. | Middletown, CA | $2.40M |
| Adventist Health Clearlake Hospital INC | Clearlake, CA | $2.25M |
| Adventist Health Clearlake Hospital INC | Hidden Valley Lake, CA | $2.03M |
| Adventist Health Clearlake Hospital INC. | Kelseyville, CA | $1.63M |
| Ukiah Adventist Hospital | Ukiah, CA | $1.40M |
| Adventist Health Clearlake Hospital, INC | Lakeport, CA | $1.05M |
| Ukiah Adventist Hospital | Fort Bragg, CA | $844K |
| Willits Hospital INC. | Willits, CA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.